Adenosine A(2A) receptor mRNA expression in Parkinson's disease

Michael J. Hurley, Deborah C Mash, Peter Jenner

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The expression of the human adenosine A(2A) receptor was examined by reverse transcription polymerase chain reaction in post-mortem human brain tissue that was obtained from normal subjects and patients who died with Parkinson's disease. Adenosine A(2A) receptor mRNA was detected in both striatal (nucleus accumbens, caudate nucleus and putamen) and extrastriatal (globus pallidus and substantia nigra) brain regions. A significant decrease in the level of adenosine A(2A) receptor mRNA was found in the anterior and posterior caudate nucleus and anterior dorsal putamen, whereas a significant increase was observed in the substantia nigra pars reticulata of Parkinsonian brain when compared to age-matched controls. No change in adenosine A(2A) receptor mRNA levels was seen in any other brain region examined. This study demonstrates that A(2A) receptor mRNA expression is altered in the basal ganglia of patients who died with Parkinson's disease and who were receiving treatment with dopaminergic drugs. The adenosine A(2A) receptor appears subject to regulation by dopaminergic systems in human brain, though these data do not permit a distinction to be made between the effects of neuronal degeneration or drug treatment. The adenosine A(2A) receptor may therefore form a target for the treatment of basal ganglia disease. (C) 2000 Published by Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)54-58
Number of pages5
JournalNeuroscience Letters
Volume291
Issue number1
DOIs
StatePublished - Sep 8 2000

Fingerprint

Adenosine A2A Receptors
Parkinson Disease
Messenger RNA
Brain
Caudate Nucleus
Putamen
Basal Ganglia Diseases
Corpus Striatum
Dopamine Agents
Globus Pallidus
Nucleus Accumbens
Substantia Nigra
Basal Ganglia
Reverse Transcription
Therapeutics
Polymerase Chain Reaction
Pharmaceutical Preparations

Keywords

  • Adenosine A(2A) receptor
  • Basal ganglia
  • Parkinson's disease
  • Reverse transcription-polymerase chain reaction

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Adenosine A(2A) receptor mRNA expression in Parkinson's disease. / Hurley, Michael J.; Mash, Deborah C; Jenner, Peter.

In: Neuroscience Letters, Vol. 291, No. 1, 08.09.2000, p. 54-58.

Research output: Contribution to journalArticle

Hurley, Michael J. ; Mash, Deborah C ; Jenner, Peter. / Adenosine A(2A) receptor mRNA expression in Parkinson's disease. In: Neuroscience Letters. 2000 ; Vol. 291, No. 1. pp. 54-58.
@article{90b87f67e1df4a8d940a0087134e6a6b,
title = "Adenosine A(2A) receptor mRNA expression in Parkinson's disease",
abstract = "The expression of the human adenosine A(2A) receptor was examined by reverse transcription polymerase chain reaction in post-mortem human brain tissue that was obtained from normal subjects and patients who died with Parkinson's disease. Adenosine A(2A) receptor mRNA was detected in both striatal (nucleus accumbens, caudate nucleus and putamen) and extrastriatal (globus pallidus and substantia nigra) brain regions. A significant decrease in the level of adenosine A(2A) receptor mRNA was found in the anterior and posterior caudate nucleus and anterior dorsal putamen, whereas a significant increase was observed in the substantia nigra pars reticulata of Parkinsonian brain when compared to age-matched controls. No change in adenosine A(2A) receptor mRNA levels was seen in any other brain region examined. This study demonstrates that A(2A) receptor mRNA expression is altered in the basal ganglia of patients who died with Parkinson's disease and who were receiving treatment with dopaminergic drugs. The adenosine A(2A) receptor appears subject to regulation by dopaminergic systems in human brain, though these data do not permit a distinction to be made between the effects of neuronal degeneration or drug treatment. The adenosine A(2A) receptor may therefore form a target for the treatment of basal ganglia disease. (C) 2000 Published by Elsevier Science Ireland Ltd.",
keywords = "Adenosine A(2A) receptor, Basal ganglia, Parkinson's disease, Reverse transcription-polymerase chain reaction",
author = "Hurley, {Michael J.} and Mash, {Deborah C} and Peter Jenner",
year = "2000",
month = "9",
day = "8",
doi = "10.1016/S0304-3940(00)01371-9",
language = "English",
volume = "291",
pages = "54--58",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Adenosine A(2A) receptor mRNA expression in Parkinson's disease

AU - Hurley, Michael J.

AU - Mash, Deborah C

AU - Jenner, Peter

PY - 2000/9/8

Y1 - 2000/9/8

N2 - The expression of the human adenosine A(2A) receptor was examined by reverse transcription polymerase chain reaction in post-mortem human brain tissue that was obtained from normal subjects and patients who died with Parkinson's disease. Adenosine A(2A) receptor mRNA was detected in both striatal (nucleus accumbens, caudate nucleus and putamen) and extrastriatal (globus pallidus and substantia nigra) brain regions. A significant decrease in the level of adenosine A(2A) receptor mRNA was found in the anterior and posterior caudate nucleus and anterior dorsal putamen, whereas a significant increase was observed in the substantia nigra pars reticulata of Parkinsonian brain when compared to age-matched controls. No change in adenosine A(2A) receptor mRNA levels was seen in any other brain region examined. This study demonstrates that A(2A) receptor mRNA expression is altered in the basal ganglia of patients who died with Parkinson's disease and who were receiving treatment with dopaminergic drugs. The adenosine A(2A) receptor appears subject to regulation by dopaminergic systems in human brain, though these data do not permit a distinction to be made between the effects of neuronal degeneration or drug treatment. The adenosine A(2A) receptor may therefore form a target for the treatment of basal ganglia disease. (C) 2000 Published by Elsevier Science Ireland Ltd.

AB - The expression of the human adenosine A(2A) receptor was examined by reverse transcription polymerase chain reaction in post-mortem human brain tissue that was obtained from normal subjects and patients who died with Parkinson's disease. Adenosine A(2A) receptor mRNA was detected in both striatal (nucleus accumbens, caudate nucleus and putamen) and extrastriatal (globus pallidus and substantia nigra) brain regions. A significant decrease in the level of adenosine A(2A) receptor mRNA was found in the anterior and posterior caudate nucleus and anterior dorsal putamen, whereas a significant increase was observed in the substantia nigra pars reticulata of Parkinsonian brain when compared to age-matched controls. No change in adenosine A(2A) receptor mRNA levels was seen in any other brain region examined. This study demonstrates that A(2A) receptor mRNA expression is altered in the basal ganglia of patients who died with Parkinson's disease and who were receiving treatment with dopaminergic drugs. The adenosine A(2A) receptor appears subject to regulation by dopaminergic systems in human brain, though these data do not permit a distinction to be made between the effects of neuronal degeneration or drug treatment. The adenosine A(2A) receptor may therefore form a target for the treatment of basal ganglia disease. (C) 2000 Published by Elsevier Science Ireland Ltd.

KW - Adenosine A(2A) receptor

KW - Basal ganglia

KW - Parkinson's disease

KW - Reverse transcription-polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=0034623337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034623337&partnerID=8YFLogxK

U2 - 10.1016/S0304-3940(00)01371-9

DO - 10.1016/S0304-3940(00)01371-9

M3 - Article

C2 - 10962152

AN - SCOPUS:0034623337

VL - 291

SP - 54

EP - 58

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 1

ER -